This content is from: Patents

In-house roundup: Trump trade war uncertainty; 5G guidance not usable; Senate eligibility hearing takeaways; unitary SPC overview

Managing IP rounds up the latest news and analysis from patent-focused businesses


Drugs

Trump trade war is “lose-lose situation” for IP in China and the US 

With Trump blacklisting Huawei from the US, telecom companies tell Patent Strategy they are fearful that a trade war escalation will affect IP and are uncertain how to prepare for such an outcome. Read More... 

Diverging SEP guidelines will have little to no impact on negotiations say stakeholders 

Reacting to the publication of new SEP licensing guidance, counsel at Audi, Philips and BSH Home Appliances explain how the documents will affect them and that they would like to see a more united direction emerge. Read more... 

Patent eligibility hearings “belied depth of opposition to Section 101 change” 

Industry speakers from the Senate IP Subcommittee hearings last month tell Patent Strategy how they thought the inquiry was conducted and what needs to happen next to ensure US innovation is protected. Read more... 

Unitary SPCs: How, where and when they could work 

Industry sources at the Pharmaceutical Patent Term Extension conference in Munich question the practical details of unitary SPCs, including granting procedure, enforcement, and judicial review. Read more... 



The material on this site is for law firms, companies and other IP specialists. It is for information only. Please read our Terms and Conditions and Privacy Notice before using the site. All material subject to strictly enforced copyright laws.

© 2020 Euromoney Institutional Investor PLC. For help please see our FAQs.

Instant access to all of our content. Membership Options | One Week Trial

Related